GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (NAS:ADAP) » Definitions » E10

Adaptimmune Therapeutics (Adaptimmune Therapeutics) E10 : $-0.84 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Adaptimmune Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Adaptimmune Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.180. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.84 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-04-28), Adaptimmune Therapeutics's current stock price is $1.075. Adaptimmune Therapeutics's E10 for the quarter that ended in Dec. 2023 was $-0.84. Adaptimmune Therapeutics's Shiller PE Ratio of today is .


Adaptimmune Therapeutics E10 Historical Data

The historical data trend for Adaptimmune Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptimmune Therapeutics E10 Chart

Adaptimmune Therapeutics Annual Data
Trend Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -0.84

Adaptimmune Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -0.84

Competitive Comparison of Adaptimmune Therapeutics's E10

For the Biotechnology subindustry, Adaptimmune Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adaptimmune Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's Shiller PE Ratio falls into.



Adaptimmune Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Adaptimmune Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.18/130.0000*130.0000
=-0.180

Current CPI (Dec. 2023) = 130.0000.

Adaptimmune Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201306 0.000 98.000 0.000
201312 0.000 99.200 0.000
201406 1.489 99.800 1.940
201409 -0.008 100.000 -0.010
201412 -0.004 99.900 -0.005
201506 -0.300 100.100 -0.390
201509 -0.018 100.200 -0.023
201512 -0.282 100.400 -0.365
201603 -0.240 100.400 -0.311
201606 -0.300 101.000 -0.386
201609 -0.240 101.500 -0.307
201612 -0.240 102.200 -0.305
201703 -0.300 102.700 -0.380
201706 -0.240 103.500 -0.301
201709 -0.009 104.300 -0.011
201712 -0.300 105.000 -0.371
201803 -0.240 105.100 -0.297
201806 -0.480 105.900 -0.589
201809 0.060 106.600 0.073
201812 -0.360 107.100 -0.437
201903 -0.240 107.000 -0.292
201906 -0.420 107.900 -0.506
201909 -0.360 108.400 -0.432
201912 -0.300 108.500 -0.359
202003 -0.240 108.600 -0.287
202006 -0.240 108.800 -0.287
202009 -0.240 109.200 -0.286
202012 -0.240 109.400 -0.285
202103 -0.240 109.700 -0.284
202106 -0.240 111.400 -0.280
202109 -0.300 112.400 -0.347
202112 -0.240 114.700 -0.272
202203 -0.300 116.500 -0.335
202206 -0.300 120.500 -0.324
202209 -0.240 122.300 -0.255
202212 -0.180 125.300 -0.187
202303 0.006 126.800 0.006
202306 -0.120 129.400 -0.121
202309 -0.180 130.100 -0.180
202312 -0.180 130.000 -0.180

Add all the adjusted EPS together and divide 10 will get our e10.


Adaptimmune Therapeutics  (NAS:ADAP) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Adaptimmune Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Adaptimmune Therapeutics (Adaptimmune Therapeutics) Business Description

Traded in Other Exchanges
Address
60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, non-small cell lung cancer, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.
Executives
Elliot Norry officer: Chief Medical Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Bertrand William C Jr officer: Chief Operating Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
John Lunger officer: Chief Patient Supply Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Adrian Rawcliffe officer: Chief Financial Officer 440 SOUTH BROAD STREET, UNIT 1906, PHILADELPHIA PA 19146
Kristen Hege director 500 FORBES BLVD, SOUTH SAN FRANCISCO CA 94070
Garry E Menzel director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Priti Hegde director TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Andrew R Allen director 2525 28TH STREET, SUITE 200, BOULDER CO 80301
Cintia Piccina officer: Chief Commercial Officer 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R
Gavin Wood officer: Chief Financial Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Joanna Elizabeth Brewer officer: Chief Scientific Officer 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Helena Katrina Tayton-martin officer: Chief Operating Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Lawrence M Alleva director 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
James Noble director, officer: Chief Executive Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX

Adaptimmune Therapeutics (Adaptimmune Therapeutics) Headlines

From GuruFocus